ANI Pharma CFO sells 2,850 shares in 10b5-1 plan

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an open-market sale of 2,850 shares of common stock at a weighted average price of $84.12 per share.

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported an open-market sale of 2,850 shares of common stock at a weighted average price of $84.12 per share. After the sale, he directly holds 177,543 shares, indicating that the transaction represents a small portion of his overall stake.

The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and occurred in multiple transactions at prices ranging from $83.39 to $84.63. Such plans are designed to allow insiders to sell shares over time according to preset instructions.

Insider Trade Summary 10b5-1

Net Seller: 2,850 shares

Net Sell 1 txn

Insider CAREY STEPHEN P.

Role SVP & CFO

Sold 2,850 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,850	$84.12	$240K

Holdings After Transaction: Common Stock — 177,543 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. F2. The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price.

Key Figures

Shares sold: 2,850 shares Weighted average sale price: $84.12 per share Post-transaction holdings: 177,543 shares +2 more

5 metrics

Shares sold 2,850 shares Open-market sale of common stock

Weighted average sale price $84.12 per share Average price across multiple trades

Post-transaction holdings 177,543 shares Shares directly owned after sale

Trade price range $83.39–$84.63 per share Range of prices for individual trades

Trading plan adoption date March 6, 2026 Rule 10b5-1 plan for reported sales

Key Terms

Rule 10b5-1 trading plan, open-market sale, weighted average sales price, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"The price reported above reflects the weighted average sales price."

Form 4 regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ANI Pharmaceuticals (ANIP) report for Stephen P. Carey?

ANI Pharmaceuticals reported that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock in an open-market transaction at a weighted average price of $84.12 per share. This filing documents the sale and the executive’s updated share ownership position.

How many ANI Pharmaceuticals (ANIP) shares does Stephen P. Carey hold after this sale?

Following the reported sale, Stephen P. Carey directly holds 177,543 shares of ANI Pharmaceuticals common stock. This shows that the 2,850 shares sold represent only a small fraction of his overall equity position in the company after the transaction.

At what prices were Stephen P. Carey’s ANI Pharmaceuticals (ANIP) shares sold?

The shares were sold in multiple trades at prices ranging from $83.39 to $84.63 per share. The Form 4 reports a weighted average sale price of $84.12 per share, reflecting the combined pricing across all individual trades executed that day.

Was Stephen P. Carey’s ANI Pharmaceuticals (ANIP) stock sale under a Rule 10b5-1 plan?

Yes. The filing states that the reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Stephen P. Carey on March 6, 2026. Such plans pre-schedule trades, helping separate routine portfolio management from market-timed insider decisions.

What type of transaction is reported in Stephen P. Carey’s ANI Pharmaceuticals (ANIP) Form 4?

The Form 4 reports an open-market sale of common stock, coded as transaction type “S.” This indicates a standard sale in the market or a private transaction, not an option exercise, grant, gift, or tax-withholding-related disposition of ANI Pharmaceuticals shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAREY STEPHEN P.

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/29/2026		S(1)		2,850	D	$84.12(2)	177,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

2. The shares were sold in multiple trades at prices ranging from $83.39 to $84.63. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Stephen P. Carey, by attorney-in-fact Meredith W. Cook	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)